Thank you.
Mr. McFadyen, I want to turn to you. You have obviously spent a lot of time thinking about this and are very personally affected.
You must have thought about that question, but as someone very personally affected, what advice would you give this committee about how we determine how we fund rare diseases when the efficacy may not be as—